Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.54 |
| ▸ | YAP1 | P46937 | 3/20 | 0.49 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.46 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4551974 | 1.00 | MAPK1 (0.54) | MAPK1MAPTNPSR1KMT2APOLB | |
| SCHEMBL4552706 | 0.89 | ITGA4 (0.49) | MAPK1MAPTNPSR1KMT2APOLB | |
| SCHEMBL5610851 | 0.89 | ITGA4 (0.49) | MAPK1MAPTNPSR1KMT2APOLB | |
| SCHEMBL4552705 | 0.89 | ITGA4 (0.49) | MAPK1MAPTNPSR1KMT2APOLB | |
| SCHEMBL4551155 | 0.87 | MAPT (0.49) | MAPK1MAPTNPSR1KMT2APOLB | |
| SCHEMBL4551152 | 0.87 | MAPT (0.49) | MAPK1MAPTNPSR1KMT2APOLB | |
| SCHEMBL6162484 | 0.78 | KMT2A (0.71) | MAPK1KMT2A | |
| SCHEMBL6162815 | 0.78 | KMT2A (0.71) | MAPK1KMT2A | |
| SCHEMBL6162477 | 0.78 | KMT2A (0.71) | MAPK1KMT2A | |
| SCHEMBL15346181 | 0.76 | MAPK1 (0.53) | MAPK1MAPTNPSR1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1592387-A4 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | ELAN PHARM INC (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-1592387-A2 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | Elan Pharmaceuticals, Inc. (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004066932-A2 | COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS | ELAN PHARMACEUTICALS INC. (US) | 2004-08-12 | — | — | WO | disclosed |